This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Acasti Pharma Past Earnings Performance
Past criteria checks 0/6
Key information
22.8%
Earnings growth rate
61.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 43.1% |
| Return on equity | -17.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Revenue & Expenses BreakdownBeta
How Acasti Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -17 | 5 | 11 |
| 30 Sep 22 | 0 | -17 | 5 | 10 |
| 30 Jun 22 | 0 | -11 | 6 | 8 |
| 31 Mar 22 | 0 | -10 | 7 | 6 |
| 31 Dec 21 | 0 | -12 | 9 | 4 |
| 30 Sep 21 | 0 | -11 | 8 | 2 |
| 30 Jun 21 | 0 | -18 | 7 | 3 |
| 31 Mar 21 | 0 | -20 | 7 | 4 |
| 31 Dec 20 | 0 | 3 | 8 | 6 |
| 30 Sep 20 | 0 | -6 | 9 | 9 |
| 30 Jun 20 | 0 | -21 | 10 | 12 |
| 31 Mar 20 | 0 | -26 | 8 | 16 |
| 31 Dec 19 | 0 | -56 | 7 | 23 |
| 30 Sep 19 | 0 | -46 | 6 | 26 |
| 30 Jun 19 | 0 | -42 | 5 | 29 |
| 31 Mar 19 | 0 | -39 | 4 | 29 |
| 31 Dec 18 | 0 | -31 | 4 | 25 |
| 30 Sep 18 | 0 | -34 | 3 | 22 |
| 30 Jun 18 | 0 | -20 | 3 | 17 |
| 31 Mar 18 | 0 | -17 | 3 | 12 |
| 31 Mar 17 | 0 | -8 | 2 | 5 |
| 30 Nov 16 | 0 | -7 | 2 | 5 |
| 31 Aug 16 | 0 | -7 | 2 | 6 |
| 31 May 16 | 0 | -6 | 2 | 6 |
Quality Earnings: ACST is currently unprofitable.
Growing Profit Margin: ACST is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACST is unprofitable, but has reduced losses over the past 5 years at a rate of 22.8% per year.
Accelerating Growth: Unable to compare ACST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42.3%).
Return on Equity
High ROE: ACST has a negative Return on Equity (-17.83%), as it is currently unprofitable.